ArticleNutrients2021
Biologic Treatment in Combination with Lifestyle Intervention in Moderate to Severe Plaque Psoriasis and Concomitant Metabolic Syndrome: Rationale and Methodology of the METABOLyx Randomized Controlled Clinical Trial.
Article in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Association of serum uric acid with circulating inflammatory proteins and treatment response to ixekizumab in patients with psoriasis: A multicenter prospective cohort study in China.Chinese medical journal · 2026Trial
- The impact of biologics targeting the IL-17 and IL-23 pathways on metabolic indicators in plaque psoriasis.Archives of dermatological research · 2025Trial
- Joint Relationship of Cardiovascular-kidney-metabolic Syndrome and Psoriasis with All-cause and Cause-specific Mortality in Adults: A Population-based Analysis.Acta dermato-venereologica · 2026Article
- A combination therapy strategy: precision co-targeting of CCR7 and JAK1 with a smart hydrogel for inflammatory skin diseases.Journal of nanobiotechnology · 2026Article
- Common Skin Diseases and Metabolic Syndrome: A Proinflammatory Chemokine Perspective.Metabolites · 2026Review
- Article
- Targeting Cytokine Dysregulation in Psoriasis: The Role of Dietary Interventions in Modulating the Immune Response.International journal of molecular sciences · 2025Review
- Beyond linearity: a threshold effect links serum creatinine to SIRI in osteoporotic fractures.Frontiers in medicine · 2025Article
- The Role of Metabolic Syndrome in Psoriasis Treatment Response: A One-Year Comparative Analysis of PASI Progression.Diagnostics (Basel, Switzerland) · 2024Article
- Identification of angiogenesis-related genes and molecular subtypes for psoriasis based on random forest algorithm.Clinical and experimental immunology · 2024Article
- Prevalence of metabolic syndrome and chronic inflammation in psoriasis before and after biologic therapy: a prospective study.Medicine and pharmacy reports · 2023Article
- Association of Nutrition, Obesity and Skin.Nutrients · 2023Article
- Impact of Chronic Inflammation in Psoriasis on Bone Metabolism.Frontiers in immunology · 2022Review
- Comorbid Psoriasis and Metabolic Syndrome: Clinical Implications and Optimal Management.Psoriasis (Auckland, N.Z.) · 2022Review
- Leptin Receptor (rs1137101) and Brain-Derived Neurotrophic Factor (rs925946) Gene Variants Are Associated with Obesity in the Early- but Not in the Late-Onset Population of Hungarian Psoriatic Patients.Life (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
Abstract
Inflammatory diseases including psoriasis are associated with metabolic and cardiovascular comorbidities, including obesity and metabolic syndrome. Obesity is associated with greater psoriasis disease severity and reduced response to treatment. Therefore, targeting metabolic comorbidities could improve patients' health status and psoriasis-specific outcomes. METABOLyx is a randomized controlled trial evaluating the combination of a lifestyle intervention program with secukinumab treatment in psoriasis. Here, the rationale, methodology and baseline patient characteristics of METABOLyx are presented. A total of 768 patients with concomitant moderate to severe plaque psoriasis and metabolic syndrome were randomized to secukinumab 300 mg, or secukinumab 300 mg plus a tailored lifestyle intervention program, over 24 weeks. A substudy of immunologic and metabolic biomarkers is ongoing. The primary endpoint of METABOLyx is PASI90 response at week 24. Other endpoints include patient-reported outcomes and safety. METABOLyx represents the first large scale clinical trial of an immunomodulatory biologic in combination with a standardized lifestyle intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.